PUBLIC CONTRACT · 2022
CPR 03/2022 Aquisição de Derivados do Plasma (CP 2020/9)
- Contract value
- €389.40
- Signed on
- 24 March 2022
- Procedure
- Ao abrigo de acordo-quadro (art.º 259.º)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 9192685PUBLISHED DESCRIPTION
CPR 03/2022
Parties involved
- Place of performance
- Portugal, Castelo Branco, Covilhã; Portugal
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- Grifols Portugal, Lda · Tax ID 502041285
- Bidder
- CSL Behring, Lda · Tax ID 503047201
- Bidder
- TAKEDA - FARMACEUTICA PORTUGAL, LDA · Tax ID 502801204
- Bidder
- Kedrion Biopharma GmbH - Sucursal em Portugal · Tax ID 980701996
- Bidder
- Octapharma-Prod Farmacêuticos, Lda · Tax ID 502820780
- Bidder
- SPC-South Point Care-Esp.Farmacêuticas, Lda · Tax ID 508284872
- Bidder
- BAXTER MEDICO - FARMACEUTICA · Tax ID 503347345
Values and timeline
- Contract price
- €389.40
- Procedure base price
- €341,813.16
- Total effective price
- €389.40
- Publication date
- 21 April 2022
- Award date
- 8 March 2022
- Signing date
- 24 March 2022
- Performance period
- 365 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Ao abrigo de acordo-quadro (art.º 259.º)
- Award criterion
- Monofator
- CPV code
- 33600000-6 - Produtos farmacêuticos
- Legal basis
- Artigo 259.º do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
- Framework agreement
- CP 2020/9 - Derivados do plasma humano
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 5740564
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.